Phase II of AUY922 in Second-line Gastric Cancer in Combination With Trastuzumab in HER2 Positive Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01402401
Recruitment Status : Terminated
First Posted : July 26, 2011
Last Update Posted : February 24, 2014
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )

July 24, 2011
July 26, 2011
February 24, 2014
November 2011
June 2013   (Final data collection date for primary outcome measure)
efficacy of AUY922 in combination with trastuzumab as assessed by RECIST [ Time Frame: every 6 weeks ]
Same as current
Complete list of historical versions of study NCT01402401 on Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
Phase II of AUY922 in Second-line Gastric Cancer in Combination With Trastuzumab in HER2 Positive Patients
An Open-label, Single-arm, Multi-center Phase II Study to Evaluate the Efficacy and Safety of AUY922 in Combination With Trastuzumab Standard Therapy as Second-line Treatment in Patients With HER2-positive Advanced Gastric Cancer
This study will assess the safety and efficacy of AUY922, when administered, in combination with trastuzumab in adult patients with HER2+ advanced gastric cancer, who have received trastuzumab plus chemotherapy in the first line.
Not Provided
Phase 2
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Advanced Gastric Cancer
Drug: AUY922 + Trastuzumab
Experimental: AUY922 + Trastuzumab
Intervention: Drug: AUY922 + Trastuzumab
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
June 2013
June 2013   (Final data collection date for primary outcome measure)

Inclusion Criteria:

Patients eligible for inclusion in this study have to meet all of the following criteria:

  1. Written informed consent obtained prior to any screening procedures
  2. Patients with documented cytological or histological confirmed gastric adenocarcinoma or gastroesophageal junction adenocarcinoma and proven HER2 positive.
  3. Patients with progressive disease (radiological confirmation required according to RECIST) after first line of trastuzumab in combination with chemotherapy for advanced gastric cancer.
  4. Age ≥ 18 years or age of consent in country of residence and able to sign Informed Consent
  5. ECOG performance status of 0-1 at study entry
  6. HER2-overexpressing positive gastric tumor by IHC3+ or IHC2+ with positive in situ hybridization
  7. Measurable disease according to RECIST (Irradiated lesions can not be considered measurable unless they have clearly progressed since radiotherapy).
  8. Negative serum pregnancy test. The serum pregnancy test must be obtained prior to any drug administration (≤ 72 hours prior to dosing) in all pre-menopausal women and for women < 2 years after the onset of menopause.
  9. Patients must have the following laboratory values:


  • Absolute Neutrophil Count (ANC) ≥1.5x109/L,
  • Hemoglobin (Hgb) ≥ 9 g/dL,
  • Platelets (plt) ≥100x109/L


  • Serum total bilirubin ≤ 1.5 x ULN
  • Serum albumin > 2.5 g/dl
  • Serum creatinine ≤ 1.5 x ULN or 24-hour clearance ≥ 50 ml/min.
  • AST/SGOT and ALT/SGPT ≤ 2.5 x Upper Limit of Normal (ULN) or ≤ 5.0 x ULN if liver metastases are present

Exclusion Criteria:

Patients eligible for this study must not meet any of the following criteria:

  1. Evidence of spinal cord compression or current evidence of CNS metastases. CT/MRI of the brain is mandatory (within 3 weeks before study start) in case of clinical suspicion or evidence of brain metastases
  2. Patient who are < 4 weeks since last chemotherapy or treatment with another systemic anti-cancer agent. Patients must have recovered (CTC ≤ 1) from acute toxicities of any previous therapy (with the exception of alopecia).
  3. Patients may have received prior radiotherapy for management of local disease providing that disease progression has been documented, all toxicities have resolved (CTC ≤ 1) (with the exception of alopecia), and the last fraction of radiotherapy was completed at least 4 weeks prior to the study.
  4. Prior treatment with an agent that acts via HER2/c-erbB2 targeting other than 1st line trastuzumab, include (but are not limited to) lapatinib and pertuzumab.
  5. Treatment with therapeutic doses of coumarin-type anticoagulants. (Maximum daily dose of 2 mg, for line patency permitted)
  6. Patients with malignant ascites that require invasive treatment
  7. Patients with acute or chronic renal disease; and active and chronic liver disease requiring intervention. Other concurrent severe and/or uncontrolled medical conditions that could cause unacceptable safety risks or compromise compliance with the protocol.
  8. Major surgery ≤ 2 weeks prior to enrollment or who have not recovered from such therapy
  9. Impaired cardiac function
  10. Concurrent malignancies or invasive cancers diagnosed within the past 5 years, except for adequately treated basal cell cancer of the skin or in situ cancer of the cervix
  11. Patients receiving chronic or high dose corticosteroids therapy (Inhaled steroids and short courses of oral steroids for anti-emesis or as an appetite stimulant are allowed)
  12. Patients unwilling or unable to comply with the protocol
  13. Patients known to be HIV positive. Testing is not required in the absence of clinical signs and symptoms suggesting HIV infection.
  14. Known hypersensitivity to any of the study drugs or their excipients
  15. Participation in another clinical study within 30 days before first study treatment
  16. Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test (> 5 mIU/mL).
  17. Fertile women of childbearing potential (WOCBP) not using adequate contraception (abstinence, oral contraceptives, intrauterine device or barrier method of contraception in conjunction with spermicidal jelly or surgically sterile).
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
Belgium,   France,   Germany,   Italy,   Japan,   Korea, Republic of,   Spain,   United States
2011-002570-23 ( EudraCT Number )
Not Provided
Not Provided
Not Provided
Novartis ( Novartis Pharmaceuticals )
Novartis Pharmaceuticals
Not Provided
Study Director: Novartis Pharmaceuticals Novartis Pharmaceuticals
February 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP